Literature DB >> 16705353

High glucose and Nepsilon-(carboxymethyl) lysine bovine serum albumin modulate release of matrix metalloproteinases in cultured human endothelial cells.

Sedegheh Gharagozlian1, Tore Henriksen, Svein Olav Kolset.   

Abstract

BACKGROUND: Hyperglycaemia may contribute to endothelial dysfunction. Disturbances in endothelial functions include changes in the extracellular matrix underneath the cells. This may result from altered biosynthesis of matrix molecules or from modified biosynthesis and secretion of enzymes involved in the turnover of extracellular matrix. One important class of such enzymes are the matrix metalloproteinases (MMPs). AIM OF THE STUDY: The aim of this study was to investigate whether the condition of high glucose concentration relevant both to diabetes type 1 and 2 and metabolic syndrome, would affect the synthesis and release of MMPs in human umbilical cord endothelial cells (HUVEC) in vitro.
METHODS: The HUVEC were isolated and cultured in vitro. The cells were exposed to medium with either low glucose (LG, 1 g/l) or high glucose (HG, 4.5 g/l) or the advanced glycation end product (AGE) N(epsilon)-(carboxymethyl) lysine bovine serum albumin (CML-BSA), at a concentration of 10 microg/ml. The HUVEC-conditioned media were harvested and subjected to gelatin zymography and Western blotting.
RESULTS: When HUVEC were incubated with HG or CML-BSA under serum free conditions a decreased secretion of pro MMP-2 was observed, both with gelatin zymography and Western blotting. The HUVEC also secreted MMP-9, but at lower levels, and effects of HG treatment were not significant. When HUVEC were stimulated with phorbol 12-myristate 13-acetate (PMA) secretion of pro MMP-2 was not increased, but the activation of pro MMP-2 into lower molecular forms increased, irrespective of culturing in LG, HG or CML-BSA.
CONCLUSION: The HUVEC exposed to high glucose or AGE exhibit decreased secretion of MMP-2. These findings may be relevant in understanding the altered turnover of the endothelial extracellular matrix observed in the diabetic state.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16705353     DOI: 10.1007/s00394-006-0597-8

Source DB:  PubMed          Journal:  Eur J Nutr        ISSN: 1436-6207            Impact factor:   5.614


  37 in total

1.  The effect of advanced glycation end-product formation upon cell-matrix interactions.

Authors:  R G Paul; A J Bailey
Journal:  Int J Biochem Cell Biol       Date:  1999-06       Impact factor: 5.085

2.  Matrix metalloproteinase hypothesis of plaque rupture: players keep piling up but questions remain.

Authors:  P K Shah; Z S Galis
Journal:  Circulation       Date:  2001-10-16       Impact factor: 29.690

Review 3.  Advanced glycation end products and diabetic nephropathy.

Authors:  Merlin C Thomas; Josephine M Forbes; Mark E Cooper
Journal:  Am J Ther       Date:  2005 Nov-Dec       Impact factor: 2.688

Review 4.  Glucose, glycation, and RAGE: implications for amplification of cellular dysfunction in diabetic nephropathy.

Authors:  Thoralf Wendt; Nozomu Tanji; Jiancheng Guo; Barry I Hudson; Angelika Bierhaus; Ravichandran Ramasamy; Bernd Arnold; Peter P Nawroth; Shi Fang Yan; Vivette D'Agati; Ann Marie Schmidt
Journal:  J Am Soc Nephrol       Date:  2003-05       Impact factor: 10.121

5.  Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy.

Authors:  Helen Vlassara; Weijing Cai; Jill Crandall; Teresia Goldberg; Robert Oberstein; Veronique Dardaine; Melpomeni Peppa; Elliot J Rayfield
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-12       Impact factor: 11.205

6.  High glucose decreases matrix metalloproteinase-2 activity in rat mesangial cells via transforming growth factor-beta1.

Authors:  R Singh; R H Song; N Alavi; A A Pegoraro; A K Singh; D J Leehey
Journal:  Exp Nephrol       Date:  2001

Review 7.  Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly.

Authors:  Zorina S Galis; Jaikirshan J Khatri
Journal:  Circ Res       Date:  2002-02-22       Impact factor: 17.367

Review 8.  Advanced glycation end products: a Nephrologist's perspective.

Authors:  D S Raj; D Choudhury; T C Welbourne; M Levi
Journal:  Am J Kidney Dis       Date:  2000-03       Impact factor: 8.860

9.  Nitric oxide inhibits matrix metalloproteinase-2 expression via the induction of activating transcription factor 3 in endothelial cells.

Authors:  Hsuan-Hsu Chen; Danny Ling Wang
Journal:  Mol Pharmacol       Date:  2004-05       Impact factor: 4.436

10.  Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix-degrading metalloproteinases and implications for plaque rupture.

Authors:  P K Shah; E Falk; J J Badimon; A Fernandez-Ortiz; A Mailhac; G Villareal-Levy; J T Fallon; J Regnstrom; V Fuster
Journal:  Circulation       Date:  1995-09-15       Impact factor: 29.690

View more
  5 in total

1.  Heparan sulfate expression is affected by inflammatory stimuli in primary human endothelial cells.

Authors:  Trine M Reine; Marion Kusche-Gullberg; Almir Feta; Trond Jenssen; Svein O Kolset
Journal:  Glycoconj J       Date:  2011-12-22       Impact factor: 2.916

2.  Effect of Gastrodia elata on tumor necrosis factor-alpha-induced matrix metalloproteinase activity in endothelial cells.

Authors:  Yun Jung Lee; Sun Mi Hwang; Dae Gill Kang; Jin Sook Kim; Ho Sub Lee
Journal:  J Nat Med       Date:  2009-08-12       Impact factor: 2.343

3.  Rapamycin prevents endothelial cell migration by inhibiting the endothelial-to-mesenchymal transition and matrix metalloproteinase-2 and -9: an in vitro study.

Authors:  Hua Gao; Jingjing Zhang; Ting Liu; Weiyun Shi
Journal:  Mol Vis       Date:  2011-12-24       Impact factor: 2.367

4.  Matrix metalloproteinases in subjects with type 1 diabetes.

Authors:  Sedegheh Gharagozlian; Katja Svennevig; Hans-Jacob Bangstad; Jan-Olof Winberg; Svein Olav Kolset
Journal:  BMC Clin Pathol       Date:  2009-09-16

5.  Integrin-associated protein association with SRC homology 2 domain containing tyrosine phosphatase substrate 1 regulates igf-I signaling in vivo.

Authors:  Laura A Maile; Byron E Capps; Emily C Miller; Ariel W Aday; David R Clemmons
Journal:  Diabetes       Date:  2008-07-15       Impact factor: 9.461

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.